Total Payments
$48,592
2024 Payments
$14,812
Companies
45
Transactions
1,893
Medicare Patients
6,622
Medicare Billing
$5.5M
Payment Breakdown by Category
Food & Beverage$34,864 (71.7%)
Other$8,290 (17.1%)
Consulting$4,483 (9.2%)
Travel$586.39 (1.2%)
Education$369.67 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $34,864 | 1,875 | 71.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,050 | 3 | 16.6% |
| Consulting Fee | $4,483 | 3 | 9.2% |
| Travel and Lodging | $586.39 | 2 | 1.2% |
| Education | $369.67 | 9 | 0.8% |
| Grant | $239.52 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $10,151 | 46 | $0 (2024) |
| UCB, Inc. | $5,868 | 146 | $0 (2024) |
| Amgen Inc. | $5,356 | 233 | $0 (2024) |
| ABBVIE INC. | $5,005 | 277 | $0 (2024) |
| Janssen Biotech, Inc. | $3,119 | 142 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,393 | 149 | $0 (2024) |
| PFIZER INC. | $2,189 | 158 | $0 (2024) |
| Lilly USA, LLC | $1,592 | 86 | $0 (2024) |
| Horizon Therapeutics plc | $1,361 | 94 | $0 (2023) |
| GENZYME CORPORATION | $1,297 | 74 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,812 | 244 | AstraZeneca Pharmaceuticals LP ($9,502) |
| 2023 | $5,527 | 263 | ABBVIE INC. ($840.22) |
| 2022 | $7,966 | 258 | UCB, Inc. ($3,411) |
| 2021 | $5,271 | 243 | Amgen Inc. ($1,502) |
| 2020 | $2,971 | 177 | AbbVie Inc. ($409.40) |
| 2019 | $4,768 | 251 | Janssen Biotech, Inc. ($995.91) |
| 2018 | $4,071 | 250 | Amgen Inc. ($445.90) |
| 2017 | $3,205 | 207 | Amgen Inc. ($377.16) |
All Payment Transactions
1,893 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $31.16 | General |
| Category: Dermatology | ||||||
| 12/20/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $29.69 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $32.68 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/16/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.76 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $129.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: Immunology | ||||||
| 12/02/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Immunology | ||||||
| 11/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $31.84 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | Pacira Pharmaceuticals Incorporated | Zilretta (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Pain Management | ||||||
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $7.72 | General |
| Category: Dermatology | ||||||
| 11/18/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $27.73 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $34.28 | General |
| Category: Dermatology | ||||||
| 11/13/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $36.28 | General |
| Category: Immunology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $22.88 | General |
| Category: Immunology | ||||||
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,730 | 120,940 | $4.1M | $1.6M |
| 2022 | 20 | 1,812 | 110,018 | $2.4M | $1.1M |
| 2021 | 19 | 1,615 | 105,664 | $3.0M | $1.4M |
| 2020 | 17 | 1,465 | 97,302 | $3.0M | $1.4M |
Total Patients
6,622
Total Services
433,924
Medicare Billing
$5.5M
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 196 | 20,640 | $899,640 | $370,701 | 41.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 36 | 32,650 | $834,628 | $334,971 | 40.1% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 12 | 7,150 | $624,975 | $240,355 | 38.5% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 13 | 40,200 | $426,000 | $156,793 | 36.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 11 | 4,120 | $283,037 | $100,767 | 35.6% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 12 | 12,810 | $298,830 | $100,614 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 509 | 1,037 | $279,990 | $95,984 | 34.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 69 | 415 | $143,175 | $43,532 | 30.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 216 | 666 | $125,874 | $38,125 | 30.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 127 | 236 | $85,904 | $30,733 | 35.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 163 | 163 | $67,645 | $19,612 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 171 | 245 | $45,080 | $15,427 | 34.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 97 | $10,670 | $2,114 | 19.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 12 | $4,140 | $1,257 | 30.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,276 | $1,086 | 33.2% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2023 | 55 | 75 | $2,430 | $759.67 | 31.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 42 | 53 | $3,392 | $491.06 | 14.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 44 | 344 | $5,160 | $226.87 | 4.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 13 | 15 | $600.00 | $129.30 | 21.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 180 | 17,880 | $509,760 | $303,391 | 59.5% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 31 | 25,233 | $529,893 | $295,204 | 55.7% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 15 | 47,600 | $522,400 | $214,292 | 41.0% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2022 | 13 | 16,170 | $190,470 | $113,826 | 59.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 501 | 950 | $256,500 | $87,579 | 34.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 137 | 207 | $75,348 | $26,415 | 35.1% |
About Dr. Jagindra Mangru, MD
Dr. Jagindra Mangru, MD is a Rheumatology healthcare provider based in Cumming, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922028034.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jagindra Mangru, MD has received a total of $48,592 in payments from pharmaceutical and medical device companies, with $14,812 received in 2024. These payments were reported across 1,893 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($34,864).
As a Medicare-enrolled provider, Mangru has provided services to 6,622 Medicare beneficiaries, totaling 433,924 services with total Medicare billing of $5.5M. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Cumming, GA
- Active Since 07/20/2006
- Last Updated 01/23/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1922028034
Products in Payments
- SAPHNELO (Biological) $9,863
- Cimzia (Drug) $2,927
- RINVOQ (Biological) $2,454
- Enbrel (Biological) $2,128
- COSENTYX (Biological) $1,797
- XELJANZ (Drug) $1,791
- ACTHAR (Biological) $1,674
- Otezla (Drug) $1,497
- TALTZ (Drug) $1,194
- KRYSTEXXA (Biological) $1,054
- TREMFYA (Drug) $1,048
- STELARA (Biological) $1,042
- ORENCIA (Biological) $937.21
- Humira (Biological) $926.09
- BENLYSTA (Biological) $888.15
- SKYRIZI (Biological) $827.19
- EVENITY (Biological) $807.35
- RAYOS (Drug) $774.00
- SIMPONI ARIA (Biological) $689.62
- Rituxan (Biological) $640.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.